Literature DB >> 18083034

Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors.

Henrik Müller1, Ilza K Pajeva, Christoph Globisch, Michael Wiese.   

Abstract

Twenty-eight compounds, including 24 structurally related derivatives of tariquidar synthesized in our laboratory, and four XR compounds, reported by Xenova group Ltd, were investigated by the Hoechst 33342 and Calcein AM functional assays for estimation of their inhibitory effects on the transport activity of P-glycoprotein (P-gp). A high correlation between the effects obtained in both assays was observed at the substrate concentrations used. The analyses of kinetics data from experiments at different substrate concentrations revealed non-competitive inhibition in the Calcein AM assay and competitive inhibition in the Hoechst 33342 assay. The 3D structures of the compounds were further aligned on Hoechst 33342 using flexible and pharmacophore alignments. The results suggested that inhibitors could interact with the H-binding site of P-gp and this could potentially be achieved by different ways of binding. The best 3D-QSAR models, generated by CoMFA and CoMSIA, yielded an internal predictive squared correlation coefficient higher than 0.8 and included electrostatic, steric, hydrogen bond acceptor, and hydrophobic fields. Validation of the models on an external test set of 30 XR compounds gave predictive squared correlation coefficients of up to 0.66. An excellent correspondence between the experimental and modeled activities of the test compounds was observed. The models can be used for prediction and rational design of new P-gp inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083034     DOI: 10.1016/j.bmc.2007.11.057

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

Review 1.  Structure-activity relationships of tariquidar analogs as multidrug resistance modulators.

Authors:  Ilza K Pajeva; Michael Wiese
Journal:  AAPS J       Date:  2009-06-06       Impact factor: 4.009

Review 2.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

3.  A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.

Authors:  Fabio Broccatelli; Emanuele Carosati; Annalisa Neri; Maria Frosini; Laura Goracci; Tudor I Oprea; Gabriele Cruciani
Journal:  J Med Chem       Date:  2011-02-22       Impact factor: 7.446

4.  A novel pharmacotherapy approach using P-glycoprotein (PGP/ABCB1) efflux inhibitor combined with ivermectin to reduce alcohol drinking and preference in mice.

Authors:  Joshua Silva; Sheraz Khoja; Liana Asatryan; Eunjoo Pacifici; Daryl L Davies
Journal:  Alcohol       Date:  2020-04-08       Impact factor: 2.405

5.  HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1.

Authors:  Gisela Caceres; Robert W Robey; Lubomir Sokol; Kathy L McGraw; Justine Clark; Nicholas J Lawrence; Said M Sebti; Michael Wiese; Alan F List
Journal:  Cancer Res       Date:  2012-07-03       Impact factor: 12.701

6.  In silico quantitative structure-activity relationship studies on P-gp modulators of tetrahydroisoquinoline-ethyl-phenylamine series.

Authors:  Changdev G Gadhe; Thirumurthy Madhavan; Gugan Kothandan; Seung Joo Cho
Journal:  BMC Struct Biol       Date:  2011-01-26

7.  Combined QSAR and molecule docking studies on predicting P-glycoprotein inhibitors.

Authors:  Wen Tan; Hu Mei; Li Chao; Tengfei Liu; Xianchao Pan; Mao Shu; Li Yang
Journal:  J Comput Aided Mol Des       Date:  2013-12-10       Impact factor: 3.686

8.  Prediction of P-glycoprotein inhibitors with machine learning classification models and 3D-RISM-KH theory based solvation energy descriptors.

Authors:  Vijaya Kumar Hinge; Dipankar Roy; Andriy Kovalenko
Journal:  J Comput Aided Mol Des       Date:  2019-11-19       Impact factor: 3.686

9.  Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.

Authors:  Chun-ling Dai; Yong-ju Liang; Li-ming Chen; Xu Zhang; Wen-jing Deng; Xiao-dong Su; Zhi Shi; Chung-pu Wu; Charles R Ashby; Shin-ichi Akiyama; Suresh V Ambudkar; Zhe-sheng Chen; Li-wu Fu
Journal:  Biochem Pharmacol       Date:  2009-05-03       Impact factor: 5.858

10.  Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar.

Authors:  Yue-Li Sun; Jun-Jiang Chen; Priyank Kumar; Kang Chen; Kamlesh Sodani; Atish Patel; Yang-Lu Chen; Si-Dong Chen; Wen-Qi Jiang; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.